Lyell Immunopharma (LYEL) Share-based Compensation (2020 - 2026)

Lyell Immunopharma's Share-based Compensation history runs 7 years deep, the most recent figure standing at $4.3 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 28.7% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $40.1 million (up 33.61% YoY), while the FY2025 annual figure was $41.8 million, up 26.2% from the prior year.
• Share-based Compensation came in at $4.3 million for Q1 2026 at Lyell Immunopharma, down from $25.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $25.6 million in Q4 2025 to a low of $4.3 million in Q1 2026.
• A 5-year average of $12.3 million and a median of $9.2 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 53.91% in 2023 and jumped 216.33% in 2025, its largest moves.
• Lyell Immunopharma's Share-based Compensation stood at $18.4 million in 2022, then plunged by 53.91% to $8.5 million in 2023, then dropped by 4.49% to $8.1 million in 2024, then surged by 216.33% to $25.6 million in 2025, then plunged by 83.2% to $4.3 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $4.3 million, $25.6 million, and $5.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison